Kiora Pharmaceuticals, Inc.
KPRX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $38 | $0 | $0 | $0 |
| Gross Profit | -$38 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $1,072 | $905 | $566 | $1,179 |
| G&A Expenses | $0 | $1,354 | $1,489 | $1,327 |
| SG&A Expenses | $1,406 | $1,354 | $1,489 | $1,327 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $138 | $275 | $58 |
| Operating Expenses | $2,477 | $2,396 | $2,330 | $2,565 |
| Operating Income | -$2,515 | -$2,396 | -$2,330 | -$2,565 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $1,899 | $132 | $260 | $406 |
| Pre-Tax Income | -$616 | -$2,265 | -$2,070 | -$2,158 |
| Tax Expense | -$643 | -$112 | $123 | $2,065 |
| Net Income | $27 | -$2,152 | -$2,193 | -$4,224 |
| % Margin | – | – | – | – |
| EPS | 0.01 | -0.54 | -0.52 | -1.41 |
| % Growth | 101.9% | -3.8% | 63.1% | – |
| EPS Diluted | 0.01 | -0.54 | -0.52 | -1.41 |
| Weighted Avg Shares Out | 4,290 | 3,989 | 4,217 | 3,001 |
| Weighted Avg Shares Out Dil | 4,362 | 3,989 | 4,217 | 3,001 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $225 | $277 | $439 |
| Interest Expense | $0 | $0 | $0 | $21 |
| Depreciation & Amortization | $38 | $3 | $0 | $6 |
| EBITDA | -$578 | -$2,255 | -$2,055 | -$2,400 |
| % Margin | – | – | – | – |